Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease.

Abstract

Eight subjects with sickle-cell disease in the symptom-free steady-state received a single one-hour infusion of the new anti-sickling agent BW12C on a total of eleven occasions. A dose-dependent increase in wholeblood oxygen affinity was observed, resulting from the action of BW12C in stabilising the oxy-conformation of haemoglobin and causing a left shift of the oxygen saturation curve. At the highest dose given (20 mg/kg bodyweight), up to 23% of haemoglobin was modified to a BW12C-reacted high-affinity form without evidence of tissue hypoxia. There was biochemical and rheological evidence for a transient decrease in haemolytic rate.

• Authors: A J Keidan, I M Franklin, R D White, M Joy, E R Huehns, J Stuart
• Journal: Lancet (London, England) (Lancet) Vol. 1 Issue 8485 Pg. 831-4 (Apr 12 1986) ISSN: 0140-6736 [Print] England
• PMID: 2870317 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Aldehydes
• Benzaldehydes
• Hemoglobin, Sickle
• Oxyhemoglobins
• 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid
• Aspartate Aminotransferases
• Bilirubin
• Oxygen

Topics

• Adult
• Aldehydes (administration & dosage, pharmacology)
• Anemia, Sickle Cell (blood, drug therapy)
• Aspartate Aminotransferases (analysis)
• Benzaldehydes
• Bilirubin (analysis)
• Binding, Competitive
• Clinical Trials as Topic
• Dose-Response Relationship, Drug
• Erythrocyte Count
• Erythrocyte Deformability (drug effects)
• Hemoglobin, Sickle (metabolism)
• Hemolysis (drug effects)
• Humans
• Infusions, Parenteral
• Leukocyte Count
• Male
• Oxygen (blood)
• Oxygen Consumption
• Oxyhemoglobins (analysis)
• Thalassemia (blood, drug therapy)
• Time Factors